IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis

Yiying Wang, Lingmin Li, Yue Wang, Zeng Yuan, Wenjing Zhang, Kenneth D. Hatch, Wenxin Zheng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Serous tubal intraepithelial carcinoma (STIC) and the p53 signature in tubal mucosa have been supported to be precursor lesions in high-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum. It remains critical to find biomarkers for precursor lesions in order to detect HGSCs efficiently. IMP3 is an oncoprotein that has been explored in human malignancies. No studies have specifically addressed the expression of IMP3 in precursor or early lesions of HGSC. The main purposes of this study are to evaluate if IMP3 plays any role in the process of pelvic serous carcinogenesis by examining its expression in HGSC precursor lesions, to examine the relationship between IMP3 and p53 in those precursor lesions, and to check if IMP3 can be used as a biomarker for early diagnosis. Methods. Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62 HGSCs without STIC, and 60 benign cases as negative controls. Sections of fallopian tubes with or without STIC, as well as cancers within the ovaries, were studied. IMP3 signature was defined as strong IMP3 cytoplasmic staining in 10 or more consecutive benign-looking tubal epithelial cells. The relationship between IMP3 and p53 overexpression was examined. Results: In the 48 HGSC patients with STIC, IMP3 was positive in 46% of STIC lesions and had a similar positive rate in the invasive components of HGSC. IMP3 was also expressed in normal appearing tubal epithelia (IMP3 signature) in 15 (31%) of 48 HGSC cases with STIC and 10 (16%) of 62 cases without STIC. In contrast, no single IMP3 signature was found in the benign control group. Concordant expression of IMP3 and p53 signatures in the STIC group was found in up to one-third of the cases. There were also five (10%) STIC cases with positive IMP3 and negative p53. Conclusions: We conclude that IMP3 may be involved in the process and progression of pelvic HGSC and may serve as a complimentary biomarker in diagnosing STIC.

Original languageEnglish (US)
Article number60
JournalJournal of Experimental and Clinical Cancer Research
Volume33
Issue number1
DOIs
StatePublished - Jul 20 2014

Fingerprint

Carcinoma in Situ
Carcinogenesis
Biomarkers
Carcinoma
Fallopian Tubes
Peritoneum
Oncogene Proteins
Ovarian Neoplasms
Early Diagnosis
Ovary
Mucous Membrane
Epithelium
Epithelial Cells
Immunohistochemistry
Staining and Labeling
Control Groups

Keywords

  • High-grade serous carcinoma
  • IMP3
  • p53 signature
  • Serous tubal intraepithelial carcinoma
  • STIC

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis. / Wang, Yiying; Li, Lingmin; Wang, Yue; Yuan, Zeng; Zhang, Wenjing; Hatch, Kenneth D.; Zheng, Wenxin.

In: Journal of Experimental and Clinical Cancer Research, Vol. 33, No. 1, 60, 20.07.2014.

Research output: Contribution to journalArticle

Wang, Yiying ; Li, Lingmin ; Wang, Yue ; Yuan, Zeng ; Zhang, Wenjing ; Hatch, Kenneth D. ; Zheng, Wenxin. / IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis. In: Journal of Experimental and Clinical Cancer Research. 2014 ; Vol. 33, No. 1.
@article{f8c2bf563ea34e77a822744e159ec2ce,
title = "IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis",
abstract = "Background: Serous tubal intraepithelial carcinoma (STIC) and the p53 signature in tubal mucosa have been supported to be precursor lesions in high-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum. It remains critical to find biomarkers for precursor lesions in order to detect HGSCs efficiently. IMP3 is an oncoprotein that has been explored in human malignancies. No studies have specifically addressed the expression of IMP3 in precursor or early lesions of HGSC. The main purposes of this study are to evaluate if IMP3 plays any role in the process of pelvic serous carcinogenesis by examining its expression in HGSC precursor lesions, to examine the relationship between IMP3 and p53 in those precursor lesions, and to check if IMP3 can be used as a biomarker for early diagnosis. Methods. Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62 HGSCs without STIC, and 60 benign cases as negative controls. Sections of fallopian tubes with or without STIC, as well as cancers within the ovaries, were studied. IMP3 signature was defined as strong IMP3 cytoplasmic staining in 10 or more consecutive benign-looking tubal epithelial cells. The relationship between IMP3 and p53 overexpression was examined. Results: In the 48 HGSC patients with STIC, IMP3 was positive in 46{\%} of STIC lesions and had a similar positive rate in the invasive components of HGSC. IMP3 was also expressed in normal appearing tubal epithelia (IMP3 signature) in 15 (31{\%}) of 48 HGSC cases with STIC and 10 (16{\%}) of 62 cases without STIC. In contrast, no single IMP3 signature was found in the benign control group. Concordant expression of IMP3 and p53 signatures in the STIC group was found in up to one-third of the cases. There were also five (10{\%}) STIC cases with positive IMP3 and negative p53. Conclusions: We conclude that IMP3 may be involved in the process and progression of pelvic HGSC and may serve as a complimentary biomarker in diagnosing STIC.",
keywords = "High-grade serous carcinoma, IMP3, p53 signature, Serous tubal intraepithelial carcinoma, STIC",
author = "Yiying Wang and Lingmin Li and Yue Wang and Zeng Yuan and Wenjing Zhang and Hatch, {Kenneth D.} and Wenxin Zheng",
year = "2014",
month = "7",
day = "20",
doi = "10.1186/s13046-014-0060-2",
language = "English (US)",
volume = "33",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis

AU - Wang, Yiying

AU - Li, Lingmin

AU - Wang, Yue

AU - Yuan, Zeng

AU - Zhang, Wenjing

AU - Hatch, Kenneth D.

AU - Zheng, Wenxin

PY - 2014/7/20

Y1 - 2014/7/20

N2 - Background: Serous tubal intraepithelial carcinoma (STIC) and the p53 signature in tubal mucosa have been supported to be precursor lesions in high-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum. It remains critical to find biomarkers for precursor lesions in order to detect HGSCs efficiently. IMP3 is an oncoprotein that has been explored in human malignancies. No studies have specifically addressed the expression of IMP3 in precursor or early lesions of HGSC. The main purposes of this study are to evaluate if IMP3 plays any role in the process of pelvic serous carcinogenesis by examining its expression in HGSC precursor lesions, to examine the relationship between IMP3 and p53 in those precursor lesions, and to check if IMP3 can be used as a biomarker for early diagnosis. Methods. Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62 HGSCs without STIC, and 60 benign cases as negative controls. Sections of fallopian tubes with or without STIC, as well as cancers within the ovaries, were studied. IMP3 signature was defined as strong IMP3 cytoplasmic staining in 10 or more consecutive benign-looking tubal epithelial cells. The relationship between IMP3 and p53 overexpression was examined. Results: In the 48 HGSC patients with STIC, IMP3 was positive in 46% of STIC lesions and had a similar positive rate in the invasive components of HGSC. IMP3 was also expressed in normal appearing tubal epithelia (IMP3 signature) in 15 (31%) of 48 HGSC cases with STIC and 10 (16%) of 62 cases without STIC. In contrast, no single IMP3 signature was found in the benign control group. Concordant expression of IMP3 and p53 signatures in the STIC group was found in up to one-third of the cases. There were also five (10%) STIC cases with positive IMP3 and negative p53. Conclusions: We conclude that IMP3 may be involved in the process and progression of pelvic HGSC and may serve as a complimentary biomarker in diagnosing STIC.

AB - Background: Serous tubal intraepithelial carcinoma (STIC) and the p53 signature in tubal mucosa have been supported to be precursor lesions in high-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum. It remains critical to find biomarkers for precursor lesions in order to detect HGSCs efficiently. IMP3 is an oncoprotein that has been explored in human malignancies. No studies have specifically addressed the expression of IMP3 in precursor or early lesions of HGSC. The main purposes of this study are to evaluate if IMP3 plays any role in the process of pelvic serous carcinogenesis by examining its expression in HGSC precursor lesions, to examine the relationship between IMP3 and p53 in those precursor lesions, and to check if IMP3 can be used as a biomarker for early diagnosis. Methods. Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62 HGSCs without STIC, and 60 benign cases as negative controls. Sections of fallopian tubes with or without STIC, as well as cancers within the ovaries, were studied. IMP3 signature was defined as strong IMP3 cytoplasmic staining in 10 or more consecutive benign-looking tubal epithelial cells. The relationship between IMP3 and p53 overexpression was examined. Results: In the 48 HGSC patients with STIC, IMP3 was positive in 46% of STIC lesions and had a similar positive rate in the invasive components of HGSC. IMP3 was also expressed in normal appearing tubal epithelia (IMP3 signature) in 15 (31%) of 48 HGSC cases with STIC and 10 (16%) of 62 cases without STIC. In contrast, no single IMP3 signature was found in the benign control group. Concordant expression of IMP3 and p53 signatures in the STIC group was found in up to one-third of the cases. There were also five (10%) STIC cases with positive IMP3 and negative p53. Conclusions: We conclude that IMP3 may be involved in the process and progression of pelvic HGSC and may serve as a complimentary biomarker in diagnosing STIC.

KW - High-grade serous carcinoma

KW - IMP3

KW - p53 signature

KW - Serous tubal intraepithelial carcinoma

KW - STIC

UR - http://www.scopus.com/inward/record.url?scp=84905032536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905032536&partnerID=8YFLogxK

U2 - 10.1186/s13046-014-0060-2

DO - 10.1186/s13046-014-0060-2

M3 - Article

C2 - 25038792

AN - SCOPUS:84905032536

VL - 33

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 60

ER -